Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients

Breast Cancer Research and Treatment
Roberta RizzoAlessandra Ferlini

Abstract

Taxanes represent a group of anticancer drugs with a wide range of activity against breast cancer. Therapy side effects include haematologic toxicity (neutropenia, leucopenia), peripheral neuropathy and hypersensitivity, and demonstrate inter-individual variations. Since it is known that three genes are implicated in taxane turnover, namely ABCB1 in the transport, CYP2C8 in the metabolism and CYP1B1 in the activity, we explored the association among polymorphisms (single nucleotide polymorphisms, SNPs) in these three genes and the occurrence of taxane-induced toxicity. We studied 95 patients affected by breast cancer and under treatment with taxanes as adjuvant, metastatic or neo-adjuvant therapy. We genotyped them for SNPs in the CYP2C8 (alleles *1, *2, *3 and *4), CYP1B1 (alleles *1 and *3) and ABCB1 (1236 C>T; 2677 G>T/A; 3435 C>T) genes by real-time PCR assay. We observed a significant association between the CYP1B1*3 allele and a lower occurrence of hypersensitivity reactions to taxane treatment. We speculate that the highest production of 4-hydroxyestradiol (4-OHE2) metabolite by CYP1B1*3 allele could increase the formation of the 4-OHE2-taxane adduct and possibly inhibit taxane toxicity. We suggest that CYP1B1 might affe...Continue Reading

References

Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G Liehr, M J Ricci
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·A SparreboomO van Tellingen
Jun 8, 2001·Biochemical Pharmacology·M C McFadyenG I Murray
Jul 20, 2001·British Journal of Cancer·M C McFadyenG I Murray
Jan 5, 2002·Breast Cancer Research and Treatment·M IscanH Raunio
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bruno Bournique, Audrey Lemarié
May 29, 2003·Current Cancer Drug Targets·M AbalI Barasoain
Aug 9, 2003·Expert Opinion on Drug Safety·Maurie Markman
Jan 30, 2004·Clinical Pharmacology and Therapeutics·Catia MarzoliniRichard B Kim
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henrik GréenCurt Peterson
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharon MarshRobert Brown
Sep 5, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tristan M SissungStephan Mielke
Oct 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tessa M BoschJan H M Schellens
Jan 17, 2007·The Pharmacogenomics Journal·S MarshT W Synold
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Sharon Marsh, Howard L McLeod
Jul 20, 2007·Pharmacogenomics·Helen Steed, Michael B Sawyer
Oct 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon MarshRobert Brown
Jan 12, 2008·Molecular Cancer Therapeutics·Tristan M SissungAlex Sparreboom
Sep 19, 2009·Pharmacogenomics·Elizabeth B Daily, Christina L Aquilante
Feb 1, 2006·Personalized Medicine·Sharon Marsh

❮ Previous
Next ❯

Citations

Apr 25, 2012·Breast Cancer Research and Treatment·Daniel L HertzE Claire Dees
Feb 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D L HertzE C Dees
Jul 11, 2013·Pharmacogenomics·Daniel L Hertz
Apr 21, 2012·Pharmacogenomics·Anna González-Neira
Nov 13, 2012·Journal of Cancer Research and Clinical Oncology·Nelson L S TangWinnie Yeo
Feb 19, 2015·Expert Opinion on Drug Metabolism & Toxicology·Joseph CiccoliniGérard Milano
Oct 2, 2012·Cancer Investigation·L FuksaH Hornychova
Nov 21, 2015·Cancer Treatment Reviews·C N FrederiksE Boven
Aug 14, 2015·BioData Mining·Cielito C Reyes-GibbySanjay Shete
Sep 10, 2014·Biochimica Et Biophysica Acta·Tristan M SissungRomano Danesi
Dec 17, 2014·Pharmacogenomics·Virginia BosóSalvador F Aliño
Apr 29, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Sonam TulsyanBalraj Mittal
Jul 26, 2018·Biomarkers in Medicine·Patrick L DiazCarlo DeAngelis
May 28, 2019·Archives of Gynecology and Obstetrics·Clarissa Lourenço de CastroRosane Vianna-Jorge
Mar 17, 2018·Journal of the National Cancer Institute·Gary R ZirpoliChristine B Ambrosone
Jul 2, 2020·OncoTargets and Therapy·Weilin XuJinhai Tang
May 1, 2020·Frontiers in Pharmacology·Zeina N Al-MahayriBassam R Ali
Mar 7, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean E AbrahamHelena M Earl
Nov 30, 2019·Critical Reviews in Oncology/hematology·Eiman Y Ibrahim, Barbara E Ehrlich
Jun 16, 2021·Expert Opinion on Drug Metabolism & Toxicology·Zeina N Al-MahayriBassam R Ali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.